Cargando…

Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy

Tumor-associated hypoxia plays an important role in carcinogenesis and metastasis. The expression, activation, and stabilization of hypoxia-inducible transcription factors (HIFs) support malignant cell survival, proliferation, plasticity, and motility. Hypoxia also upregulates the expression of prog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shurin, Michael R., Umansky, Viktor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057611/ https://www.ncbi.nlm.nih.gov/pubmed/35499071 http://dx.doi.org/10.1172/JCI159473

Ejemplares similares

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

Neutrophils diminish T-cell immunity to foster gastric cancer progression: the role of GM-CSF/PD-L1/PD-1 signalling pathway
por: Zhang, Xu, et al.
Publicado: (2017)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer
por: Hakozaki, Taiki
Publicado: (2023)

Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
por: Zubiri, Leyre, et al.
Publicado: (2019)

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
por: Que, Yi, et al.
Publicado: (2021)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

HIF1α-dependent and independent pathways regulate the expression of PD-L1 in prostate cancer
por: Xanthopoulou, Erasmia T., et al.
Publicado: (2023)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy
por: Li, Zichun, et al.
Publicado: (2023)

Sepsis in PD-1 light
por: Monneret, Guillaume, et al.
Publicado: (2016)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
por: Robainas, Marianela, et al.
Publicado: (2017)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2020)

Aged glomeruli: a link between PD-1 and podocytes
por: Yu, Samuel Mon-Wei, et al.
Publicado: (2022)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia
por: Ding, Xing-chen, et al.
Publicado: (2021)

Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2022)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
por: Jia, Long, et al.
Publicado: (2018)

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
por: Qian, Jiawen, et al.
Publicado: (2018)

Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors
por: Le, Catherine T., et al.
Publicado: (2019)

The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides
por: Grywalska, Ewelina, et al.
Publicado: (2017)

The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface
por: Meggyes, Matyas, et al.
Publicado: (2019)

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
por: Kammerer-Jacquet, Solène-Florence, et al.
Publicado: (2019)

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
por: Wan, Yulin, et al.
Publicado: (2020)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy
por: Zhao, Guo, et al.
Publicado: (2023)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
por: Qin, Weiting, et al.
Publicado: (2019)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused?
por: Adorisio, Sabrina, et al.
Publicado: (2021)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
por: Wang, Xueping, et al.
Publicado: (2020)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
por: Mishra, Surbhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fqfih52fo5leg7ttje7lvr7djr